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Background: Short-term zidovudine monotherapy (ZDVm) remains an option for some pregnant HIV-positive
women not requiring treatment for their own health but may affect treatment responses once antiretroviral therapy
(ART) is subsequently started.
Methods: Data were obtained by linking two UK studies: the UK Collaborative HIV Cohort (UK CHIC) study and the
National Study of HIV in Pregnancy and Childhood (NSHPC). Treatment responses were assessed for 2028 women
initiating ART at least one year after HIV-diagnosis. Outcomes were compared using logistic regression, proportional
hazards regression or linear regression.
Results: In adjusted analyses, ART-naïve (n = 1937) and ZDVm-experienced (n = 91) women had similar increases in
CD4 count and a similar proportion achieving virological suppression; both groups had a low risk of AIDS.
Conclusions: In this setting, antenatal ZDVm exposure did not adversely impact on outcomes once ART was
initiated for the woman’s health.
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In the UK, zidovudine monotherapy (ZDVm) has been
widely used for prevention of mother-to-child-transmis-
sion (PMTCT). Although combination antiretroviral ther-
apy (ART) is now more commonly used for this purpose,
ZDVm remains an option for pregnant women not on
therapeutic ART with high CD4 counts (>350 cells/mm3)
[1], low viral loads (<10,000 copies/ml), and who are
willing to deliver by elective caesarean section [2]. The
2012 BHIVA guidelines recommend that women opting
to use ZDVm for PMTCT start ZDVm before 24 weeks* Correspondence: susan.huntington.09@ucl.ac.uk
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article, unless otherwise stated.of pregnancy [2]. Pregnant women not on ART with
CD4 ≤ 350 cells/mm3 are recommended to initiate long-
term ART, as per the general UK HIV treatment guide-
lines [3].
Little is known about the impact of short-term ZDVm
exposure on the woman’s subsequent response to ART
when started for her own health. In low- and middle-
income settings use of single-dose nevirapine (sd-NVP)
can have a negative impact on subsequent treatment re-
sponses to NVP-containing regimens, with high levels
of drug resistance, particularly when ART is initiated
within 6–12 months post-sd-NVP exposure [4,5]. How-
ever, whereas resistance to NVP requires a single mutation,
resistance to ZDV requires multiple sequential mutations.
As such, the development of resistance following short-
term ZDVm for PMTCT is uncommon [6-9] and limited
to women with more advanced disease [10-13] who wouldntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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contrast to the UK guidelines, ZDVm for PMTCT is no
longer recommended within the updated consolidated
World Health Organization (WHO) guidelines on use of
ART; in line with the WHO guidelines’ main focus on earl-
ier initiation of ART to decrease transmission, pregnant
women not yet on therapy are recommended to start long-
term combination therapy regardless of CD4 count [14].
Despite these recent changes, there are many women in
low- and middle-income settings with previous antenatal
exposure to ZDVm who have yet to start ART for their
own health [15]. In addition, use of ZDVm in pregnancy
will remain a strategy for PMTCT in some settings until
combination ART becomes more accessible.
Our aim was to test whether short-term exposure to
ZDVm in a previous pregnancy has an adverse effect on
treatment outcomes once a woman starts ART for her
own health. Record linkage between the UK and Ireland
National Study of HIV in Pregnancy and Childhood
(NSHPC) and the UK Collaborative HIV Cohort (UKTable 1 Characteristics of ART-naïve and ZDVm-experienced w
Demographic and clinical characteristics at
start of therapeutic ART
ZD
Age (years), median (IQR) 33
Time since HIV diagnosis (years), median (IQR) 5
Pregnant, n (%) 27
Ethnicity, n (%) Black 67
Non-black/not known 24
Risk group, n (%) Heterosexual sex 89
Other 2
Year, n (%) 2000-2002 13
2003-2005 32
2006-2009 46
ART regimen started, n (%)
PI based (boosted and non-boosted) 22
NNRTI 57
NRTI/other 12
Baseline CD4 count Median (IQR), (cells/mm3) 226
(n = 75, n = 1431) CD4 <200 cells/mm3, n (%) 29
CD4 <350 cells/mm3, n (%) 57
Baseline viral load Median (IQR), (log10 copies/ml) 4.1
(n = 68, n = 1371) ≤50 copies/ml, n (%) 4
≤400 copies/ml, n (%) 8
≤10,000 copies/ml, n (%) 28
Hepatitis C co-infection, n (%) 4
Hepatitis B co-infection, n (%) 1
Previous AIDS event, n (%) 7
IQR, Interquartile range; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcCHIC) study gave us the opportunity to address this issue,
which has implications for women with previous ZDVm
experience.
Methods
We compared treatment outcomes among ART-naïve and
ZDVm-experienced women starting therapeutic ART for
their own health. Data were obtained from the UK CHIC
study, an observational cohort that collates clinical data for
adults receiving HIV-care at 15 large HIV clinics [16], and
the NSHPC which collects antenatal data on all pregnant
women diagnosed HIV-positive in the UK and Ireland
[17]. Women reported to both studies were linked using
demographic and clinical variables, as described elsewhere
[18]. Data were not available on whether women had
pregnancies prior to HIV diagnosis or infection, nor
were data available on previous ART use outside the
UK. Eligibility criteria were: initiating therapeutic ART
at a UK CHIC site in 2000–2009 at least one year after
HIV-diagnosis, either ZDVm-experienced or ART-naïveomen when starting therapeutic ART in 2000-2009
Vm-experienced
(n = 91)
ART-naïve
(n = 1937)
p-value
(30–37) 35 (30–40) 0.01
(4–9) 4 (2–7) <0.001
(29.7) 147 (7.6) <0.001
(73.6) 1349 (69.6) 0.42
(26.4) 588 (30.3)
(97.8) 1718 (88.7) 0.006
(2.2) 219 (11.3)
(14.3) 375 (19.4) 0.40
(35.1) 589 (30.4)
(50.6) 973 (50.2)
(24.2) 552 (28.5) 0.48
(62.6) 1192 (61.5)
(13.2) 193 (10.0)
(162–339) 225 (150–304) 0.16
(38.7) 584 (40.8) 0.71
(76.0) 1195 (83.5) 0.09
(3.2-4.5) 4.3 (3.4-4.9) 0.08
(5.9) 126 (9.2) 0.35
(11.8) 228 (16.6) 0.29
(41.2) 535 (39.0) 0.72
(4.4) 170 (8.8) 0.14
(1.1) 55 (2.8) 0.32
(7.7) 279 (14.4) 0.07
riptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
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and aged ≤49 years at HIV-diagnosis. Women were cate-
gorised as ZDVm-experienced if, according to NSHPC or
UK CHIC data, they had ever used short-term ZDVm
during pregnancy.
Baseline CD4 count and viral load were taken as the
latest measurement within the three months before ART
initiation. Characteristics of women starting treatment
were compared using the Chi-square, Fisher’s exact or
Wilcoxon two-sample test. ART outcomes were com-
pared using logistic regression, proportional hazards re-
gression or linear regression.
The UK CHIC Study has multicentre ethics committee
approval (MREC/00/7/47). Ethics approval for NSHPC
was renewed following review by the London Multi-Centre
Research Ethics Committee in 2004 (MREC/04/2/009).Results
Overall, 1937 ART-naïve and 91 ZDVm-experienced
women started therapeutic ART in 2000–2009. ZDVm-
experienced women had used ZDVm in either one (n = 84)
or two pregnancies (n = 7). No infants acquired HIV.
ZDVm was used for a median of 12 weeks (IQR 8–16) and
was typically started at 28 weeks gestation (range 17–39,
IQR 24–31). The median duration between delivery (of the
latest pregnancy) and starting therapy was 43 months (IQR
30–63); six women started within 12 months of delivery,
none within 6 months.Table 2 Treatment outcomes for ART-naïve and ZDVm-experi
Variable ZDVm-expe
N = 9
Death/AIDS event within 1 year, n (%) 1
CD4 cell count change at 6 months, median cells/mm3 (IQR)a 106 (4
CD4 cell count change at 12 months, median cells/mm3 (IQR)b 153 (6
Virological suppression at 6 months, n (%)c 53
Virological suppression at 12 months, n (%)d 52
Achieved virological suppression within 1 year, n (%)e 75
Virological rebound among those achieving virological
suppression within 6 months, n (%)f
16
aZDVm: n = 59 and ART-naïve: n = 1272; bZDVm: n = 58 and ART-naïve: n = 1192; cZD
eZDVm: n = 70 and ART-naïve: n = 1189; fZDVm: n = 70 and ART-naïve: n = 1189.
Estimates are odds ratios (viral suppression at 6 and 12 months), hazard ratios (dea
difference in medians (CD4 cell count change at 6 and 12 months).
*Variables adjusted for are: age at start of ART, exposure group, ethnicity, time sinc
category, baseline CD4 count category and hepatitis B/C co-infection.In both groups some women were known to have had
one or more previous pregnancies during which no ART
was used (2.6% (51/1937) ART-naïve women and 11.0%
(10/91) ZDV-experienced women). These pregnancies
either ended early, due to termination or miscarriage, or
resulted in a live birth where HIV was not diagnosed
until delivery.
The baseline demographic and clinical characteristics of
ZDVm-experienced and ART-naïve women at the time of
starting therapeutic ART are summarised in Table 1. The
median follow-up time was the same for both groups
(4 [IQR 2–6] years, p = 0.77). Median time since HIV-
diagnosis was 5 [4-9] years for ZDVm-experienced and
4 [2-7] years for ART-naïve women (p < 0.001). ZDVm-
experienced women were younger than ART-naïve women
(33 [30–37] and 35 [30–40] years, respectively, p = 0.01),
more likely to have been infected heterosexually (97.8% vs.
88.7%, p = 0.006) and more likely to start therapy during
pregnancy (29.7% vs. 7.6%, p = 0.001). A similar proportion
of women were of black ethnicity (black-African, black-
Caribbean or black-other) (ZDVm-experienced: 73.6%;
ART-naïve: 69.6%, p = 0.42). Overall, 28.3% (n = 574) used
a PI-based regimen (ritonavir-boosted or non-boosted),
61.6% (n = 1249) an NNRTI-based regimen and 10.1%
(n = 205) an NRTI or other regimen. The regimens
used were similar regardless of prior ZDVm experience
(p = 0.48). ZDVm-experienced women were more likely
to have at least one viral load measurement recorded in
the first year of treatment (ZDVm-experienced: 95.6%;enced women starting therapeutic ART in 2000-2009
rienced
1
ART-naïve
N = 1937
Unadjusted/
Adjusted*
95% CI p-value
(1.1) 92 (4.8) 0.45 0.16-1.19 0.11
0.59 0.22-1.60 0.30
1–171) 106 (34–197) −0.66 −49.5-24.6 0.51
−0.68 −44.6-29.2 0.68
1–233) 160 (70–256) −1.2 −71.3-18.1 0.24
−0.83 −63.3-25.7 0.41
(74.7) 1115 (74.4) 1.01 0.59-1.75 0.96
1.00 0.56-1.73 0.97
(78.8) 1108 (77.8) 1.06 0.58-1.94 0.85
1.06 0.57-1.96 0.86
(86.2) 1408 (84.7) 1.30 1.03-1.64 0.03
1.28 1.01-1.62 0.04
(22.9) 197 (16.6) 1.54 0.93-2.57 0.10
1.51 0.90-2.53 0.12
Vm: n = 71 and ART-naïve: n = 1499; dZDVm: n = 66 and ART-naïve: n = 1424;
th/AIDS event, virological suppression within 1 year, virological rebound) or
e HIV-diagnosis, year of starting ART, previous AIDS event, baseline viral load
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dence interval 1.08-9.75], p = 0.04), however the median
number of measurements recorded was the same (ZDVm-
experienced: median 4 [IQR 3–5]; ART-naïve: median 4
[2-5], p = 0.83).
ZDVm-experienced and ART-naïve women started thera-
peutic ART at similar baseline CD4 counts (ZDVm-
experienced: 226 [162–339] cells/mm3; ART-naïve: 225
[150–302] cells/mm3, p = 0.16) and viral load (ZDVm-
experienced: 4.1 [3.2-4.5] log10 copies/ml; ART-naïve:
4.3 [3.4-4.9] log10 copies/ml, p = 0.08). Few women in
either group were known to have hepatitis B (ZDVm-
experienced: 1.1%; ART-naïve: 2.8%, p = 0.32) or hepatitis
C co-infection (ZDVm-experienced: 4.4%; ART-naïve: 8.8%,
p = 0.14). Few women had previously had an AIDS event
(ZDVm-experienced: 7.7%; ART-naïve: 14.4%, p = 0.07).
ZDVm-experienced and ART-naïve women had simi-
lar treatment outcomes (risk of an AIDS event or death,
CD4 cell count change) in the first year of therapy
(Table 2). Where viral load data were available, most
women had undetectable viral load at 12 months (77.9%,
1160/1490). ZDVm-experienced women were more likely
to achieve virological suppression (≤50 copies/ml) within
the first year of treatment (Table 2) and achieved viro-
logical suppression more quickly than ART-naïve women
(median 2.5 [IQR 1.3-3.4] months versus 3.0 [1.7-4.8]
months, respectively, hazard ratio (HR): 1.30 [95% CI
1.03-1.64], p = 0.03, aHR: 1.28 [1.01-1.62], p = 0.04).
Discussion
This UK study indicates that where ZDVm is used in
pregnancy to prevent MTCT among women with high
CD4 count and viral load <10,000 copies/ml it does not
have a deleterious effect on treatment outcomes when
ART is subsequently started. This adds support to the
limited number of studies which indicate that short-
term use of ZDVm for PMTCT is not detrimental to
women’s long-term health [7,9,19,20] and provides some
reassurance with respect to the large number of women
in lower-resourced settings with prior antenatal ZDVm
exposure who have not yet initiated treatment. However,
as a substantial proportion of these women may have
had higher viral load in pregnancy [21,22], their outcomes
may be different. The increased likelihood of achieving
viral suppression among ZDV-experienced women may
be due to better treatment adherence or frequency of viral
load monitoring. ZDVm-experienced women were more
likely to have a viral load measure reported in the first year
of treatment indicating that they had better contact with
clinical care. If having a previous pregnancy, and short-
term use of ART in that pregnancy, results in better en-
gagement in clinical care when a woman subsequently
starts therapy for her own health, this could mask any
deleterious effect of the previous ART exposure. No datawere available on previous pregnancies before HIV diag-
nosis or ART use outside the UK, something that may im-
pact treatment outcomes. Therefore, further investigation
is required to assess the long-term impact of short-term
antenatal ART used for PMTCT.
Conclusions
In this setting, antenatal ZDVm exposure did not ad-
versely impact on outcomes once ART was initiated for
the woman’s health. This was a small study with limited
statistical power and further research is required to sup-
port these findings.
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